This trial aimed to compare the effects of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, with placebo in patients with type 2 diabetes and reduced or preserved left ventricular ejection fraction who had recently been hospitalized due to worsening HF [1,14]. This evidence concerns the gene SLC5A2 and hydrops fetalis.